創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

創薬シーズ 創薬技術

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
20/09/08 GEM221 Anti-Globo H ADC Cancer i.v. Antibody Preclinical High affinity, fast internalization, good in vitro cytotoxicity
- Showed great tumor growth inhibition (>90%, 3 mg/kg) in HCC-1428 animal models without any body weight loss
- Can be prepared reproducibly at gram scale. 		問合せ
20/09/08 GEM220 Anti-Globo H Antibody Breast Cancer i.v. Antibody *Preclinical **Discovery * Anti-Globo H monolonal antibody
- Higher patient population in breast cancer (61%).
- Anti-cancer efficacy demonstrated in breast cancer animal model through ADCC and CDC.
**Anti-Globo H bispecific antibody
- High correct pairing (>95%)
-Target cell-dependent T cell activation (Better safety profile).
- Anti-cancer efficacy demonstrated in breast cancer animal model through T cell-mediated cytotoxicity. 		問合せ
20/09/08 GEM219 Anti-TIM-3 antibody Cancer i.v. Antibody Preclinical GEM219 is a fully human anti-TIM-3 antibody with high affinity in vitro and cell-based binding assay.
- The anti-TIM-3 antibodies are also highly functional in cellbased bioassay.
- Some anti-TIM-3 antibodies have cross-species recognition ability to mouse TIM-3.
- Animal efficacy studies are in progress 		問合せ
20/09/08 GEM218 Anti- Human PD-L1 antibodies Cancer i.v. Antibody Preclinical GEM218 is a novel monoclonal antibody that specifically binds to PD-L1 with high affinity and effectively blocks PD-1/PD-L1 interaction.
- Can be well detected by the PD-1/PD-L1 Blockade Assay.
- Novel binding epitopes.
- Good potential for a companion diagnosis.
- The efficacy and toxicity are studied in various in vitro and in vivo models 		問合せ
20/09/08 GEM217 AXL Kinase Inhibitor Cancer with high AXL expression Oral Small molecule Preclinical GEM217 is a selective AXL kinase inhibitor.
- The chemical structure of GEM217 is distinguished from known AXL inhibitors.
- Superior antitumor activity to reference compound BGB324, which is currently in phase II clinical trial for treating lung cancer.
- Acceptable PK property and orally antitumor activity. 		問合せ
20/09/08 GEM215 Globo H-Specific CAR-T Cells Solid Tumor: breast cancer, gastric cancer and lung cancer i.v. Cell therapy Discovery Potential cell therapy for Globo H+ solid tumor.
-Combination with anti-PD-L1 Ab overcomes PD-L1-mediated immune suppression on CAR-T cells in tumor microenvironment.
-Anti PD-L1 Ab is able to induce bystander effect during Globo H CAR-T cell treatment. 		問合せ
20/09/08 GEM214 Anti-K. pneumoniae (KP) Antibodies Multiple Drug Resistant （MDR） Klebsiella pneumoniae （KP） infection i.v. Antibody Preclinical GEM214 is an anti-MDR therapeutic antibody against Klebsiella pneumoniae Infection.
-A fully human mAb, has longer half-life and low immunogenicity.
-Antibody Antibiotics Conjugate (AAC) of GEM214 shows dose dependent intracellularly bactericidal potency. 		問合せ
20/09/08 GEM213 Anti-CSF-1R antibody Cancer, PVNS （pigmented villonodular synovitis） i.v. Antibody Preclinical GEM213 is an antibody with high affinity and neutralizing ability.
- GEM213 can potently inhibit Colony Stimulating Factor Receptor 1 (CSF-1R) in cellular contexts and has the potential to induce a therapeutic effect on macrophages.
- GEM213 has unique CDR sequences and epitopes.
- GEM213 is a promising new agent with potential to combine with immune checkpoint inhibitors to relief macrophage-dependent immune suppression and would yield clinical benefit. 		問合せ
20/09/03 GEM-CDV07 CK2 inhibitor COVID-19 Oral small molecule IND# - A promising therapeutic compound due to its dual impact on COVID-19
*Block stress granule disaggregation required for active viral replication
*Reduce cytokine storm
- GEM-CDV07 demonstrates potent anti-SARS-CoV-2 activity.
- In process of filing for emergency IND (eIND) to U.S. FDA to test ten patients.
#Phase 2 clinical trial is ongoing for other indication. 		問合せ
20/08/26 GEM212 Antivirulent approach targeting antimicrobial resistance of Staphylococcus aureus infections S. aureus and MRSA Oral Small molecule Near completion of IND stage An antivirulent, non-bactericidal small molecule drug candidate for S. aureus infections, including MRSA, in a first-in-class oral form. Potentially reduces the risk of S. aureus resistance. A new mechanism to enhance the killing action of neutrophils. Phase II clinical trials are planned across multiple indications; bacteremia, pneumonia, endocarditis, bone and joint infections. 問合せ